Stocks
Protara Therapeutics, Inc.TARA
NASDAQHealthcareBiotechnology$2.33
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing therapies for unmet needs in oncology and rare diseases. Its lead candidate, TARA-002, is being evaluated in phase 2 trials for non-muscle invasive bladder cancer and lymphatic malformations. Investors track the stock because progress on TARA-002 could significantly affect the company's valuation.
52W Range: $2.28-$7.82
Congressional Interest in Protara Therapeutics, Inc. (TARA)
No congressional trades have been disclosed for Protara Therapeutics, Inc. (TARA) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading TARA?
No congressional trades found for this stock.